Two exemptions, not two grades of quality

Section 503A and section 503B are exemptions from different obligations, and reading them as a ranking is the first mistake a purchasing file makes. A drug compounded under section 503A is exempt from the new drug approval requirement, from the requirement that labeling bear adequate directions for use, and from current good manufacturing practice. Those three are bought with one thing: the drug is compounded for an identified individual patient on a valid prescription order.

A drug compounded in a registered outsourcing facility is exempt from a different set. Section 503B lifts the approval requirement, the adequate directions requirement, and the drug supply chain tracing requirements of section 582. Current good manufacturing practice is not on that list, and that omission is the whole design.

So neither is a better version of the other. The 503A compounder keeps the prescription and is released from the manufacturing standard. The outsourcing facility gives up the prescription and takes the manufacturing standard in its place, with annual registration, risk-based inspection and adverse event reporting.

503A or 503B: which one your practice can buy from

The federal answer turns on when the material moves, not on how well it was made. FDA reads the prescription requirement as a rule about the door: the compounder must hold a valid patient-specific prescription before the compounded drug leaves the compounding facility.

So a practice cannot lawfully hold non-patient-specific office stock obtained from a 503A pharmacy, however good that pharmacy is, and it can hold office stock from a registered outsourcing facility, because section 503B says in terms that an outsourcing facility may or may not obtain prescriptions for identified individual patients.

The trap sits one level down, and it is where a purchasing file built on state law alone fails. Some boards of pharmacy authorize a prescription written without a patient name, and FDA's guidance addresses that practice directly and does not accept it as satisfying section 503A. A state can grant a state permission. It cannot grant a federal exemption.

One thing looks like office stock and is not. Anticipatory compounding under section 503A(a)(2) lets a pharmacist or physician compound in limited quantities before a prescription arrives, on a history of valid orders inside an established relationship. FDA does not define limited quantities, but it has said what it will not look at. Under an interim compliance policy stated in nonbinding guidance, FDA does not intend to consider whether the limited quantity condition was exceeded where the compounder holds for distribution no more than a 30-day supply of the drug to fill prescriptions not yet received, and where that supply is based on the number of valid patient-specific prescriptions the compounder received in a 30-day period over the past year that it selected. That inventory sits on the compounder's shelf and is released against prescriptions as they arrive. It never becomes stock on yours.

The bulk substance test is not the same test on both sides

The office-use question settled, the sourcing question remains, and the two channels answer it differently. Section 503A gives three grounds, read in order, one per substance: comply with an applicable United States Pharmacopoeia or National Formulary monograph if one exists; if none exists, be a component of an FDA-approved drug; if neither, appear on the list FDA develops by regulation. That third ground is codified at 21 CFR 216.23, which currently names six substances. It is not the whole of the ground: FDA also operates an interim policy placing nominated substances in categories while it evaluates them, and a substance in the category of those under evaluation is sourced under that policy rather than under the codified list. Either way the prong is narrow, and a substance offered as being on the FDA list when a monograph exists is being described wrongly.

Section 503B asks something else. An outsourcing facility may compound from a bulk drug substance only where the substance appears on the list of substances for which FDA has found a clinical need, established by Federal Register notice, or where the drug is on FDA's shortage list at the time of compounding, distribution and dispensing. A substance a 503A pharmacy may lawfully use because a monograph exists is not thereby available to an outsourcing facility, and the reverse holds too.

Two conditions are identical on both sides, and they are the two a supplier answers for. The bulk drug substance must be manufactured by an establishment registered under section 510 of the act, foreign establishments included, and it must come with a valid certificate of analysis. Neither channel may compound a product on the list at 21 CFR 216.24 of products removed from the market for reasons of safety or effectiveness. The essentially-a-copy limit is not one test but two: a 503A compounder may not compound regularly or in inordinate amounts a drug product that is essentially a copy of a commercially available drug product, while an outsourcing facility may not compound a drug that is essentially a copy of one or more approved drugs at all.

One asymmetry is easy to miss. Section 503A requires the bulk substance to comply with the monograph and with the United States Pharmacopoeia chapter on pharmacy compounding. Section 503B requires monograph compliance and stops, so a compendial chapter is a federal condition of one exemption and not of the other.

Where the tracing law lands, and where it does not

Compounded drugs sit outside the Drug Supply Chain Security Act twice over. The definition of product excludes a drug compounded in compliance with section 503A or section 503B, and section 503B separately exempts an outsourcing facility's drug from those same requirements. Neither route is an accident; both were written in.

Bulk drug substances never enter the frame at all. A product under that act is a prescription drug in a finished dosage form for administration to a patient without substantial further manufacturing, and an active ingredient is the thing further manufacturing acts on. No transaction information, transaction statement, product identifier or authorized-trading-partner test attaches to it. That is the scope of the statute rather than a gap in it.

The timetable has moved more than once, and the current figures are worth reading from the agency rather than from summaries. FDA has exempted small dispensers, and where applicable their trading partners, until November 27, 2027, with the small dispenser test fixed as of November 27, 2026: the company that owns the dispenser has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians. A trading partner that does not qualify has to request a waiver, exception or exemption of its own.

Licensing is a state question, and its definition is wider than you expect

The federal licensing hook is short: no person may engage in wholesale distribution of a prescription drug in any state unless licensed by the state from which the drug is distributed, or, where that state has established no licensure requirement, licensed by FDA, and, where the drug moves interstate, licensed by the state into which it is distributed if that state requires it. The hook is written around a drug, not around the narrower product the tracing statute defines.

The federal guideline for state licensing carries the sentence most worth knowing here. It defines a prescription drug as any human drug required by federal law or regulation to be dispensed only by a prescription, including finished dosage forms and active ingredients subject to section 503(b) of the act. An active ingredient can therefore sit inside a state's wholesale distribution licensing while sitting entirely outside the tracing statute.

The exclusion office-use purchasing usually rests on sits in both places. The statute excludes the distribution of minimal quantities of a drug by a licensed retail pharmacy to a licensed practitioner for office use, at 21 U.S.C. 353(e)(4)(E), and the licensing guideline carries the same exclusion at 21 CFR 205.3(f)(10). Neither says what minimal means, and the percentages people quote here come from state statutes filling that gap. The exclusion answers whether the selling pharmacy needs a wholesale distributor license. It says nothing about whether the compounded drug qualified for the section 503A exemption.

Interstate supply carries its own limit. A 503A compounder in a state that has not entered a memorandum of understanding with FDA may distribute compounded drugs out of state only in quantities not exceeding 5 percent of the total prescription orders it dispenses or distributes. FDA made a standard memorandum available for signature in October 2020, a federal district court remanded it in September 2021, and FDA intends notice-and-comment rulemaking on the provision, so confirm an out-of-state arrangement with the shipping pharmacy's own board rather than assume it. The national picture is unfinished the same way: FDA's proposed national standards for wholesale drug distributors and third-party logistics providers, dated February 2022, still sits on the agency's policy index as a proposed rule.

Four lookups that settle a supplier

Most of this is public and specific. Almost none of it is what a supplier volunteers.

• The establishment behind a bulk drug substance. Search FDA's Drug Establishments Current Registration Site by firm name. Registration under section 510 is a condition of both exemptions, so an establishment that does not appear is a stop, not a point to argue.
• A registered outsourcing facility. FDA publishes the table: initial and most recent registration date, last inspection, whether a Form 483 was issued, whether a recall was conducted, the action taken on that inspection, and whether the facility intends to compound sterile drugs from bulk substances. That last column is not a courtesy; section 503B requires FDA to publish it.
• Wholesale distributor licensure. Verify it with the board of the state you are shipping into. FDA's annual reporting database is a reporting database, and the agency says so: reporting does not mean the facility is licensed or approved by FDA. It holds neither section 510 registrants nor registered outsourcing facilities, so a supplier missing from it may be in a different register.
• The basis behind the substance. Ask which of the three grounds a bulk substance is supplied on and expect one sentence naming the authority, not a general assurance of compliance. GradeBio prints that line on the entry.

The carton answers a question the paperwork does not

A drug compounded in an outsourcing facility carries a label set by statute rather than by the seller. It must state that it is a compounded drug, and carry the facility's name, address and phone number, the lot number, the established name, the strength, the quantity, the date compounded, the expiration date, storage and handling instructions, the statement Not for resale, and, where the drug was distributed other than on a prescription for an identified individual patient, the statement Office Use Only.

Read that list from the receiving bench. Office Use Only on an arriving carton is the compounder telling you in writing, under a federal labeling condition, which pathway the material traveled. Not for resale tells you what the receiving practice may not do with it: the drug may be administered in a health care setting, or dispensed on a valid prescription, and it may not be sold or transferred onward by anyone other than the compounding facility.

What this means for a buyer

Three questions settle almost every order. Does a patient-specific prescription exist before this leaves the compounder, which decides whether the order belongs in the 503A channel at all. Which ground is the bulk substance supplied on, answered per substance and never carried across between channels. And which state's license governs the shipment, answered by the board of the state receiving it and not by any federal database.

None of the three is a judgment about quality. They are conditions, and a condition is either met on the record or it is not. The register GradeBio keeps is short for the same reason: an entry is added when its basis, its qualified source and its release testing are settled, and not before.

Sources

1. Federal Food, Drug, and Cosmetic Act, section 503A 21 U.S.C. 353a(a), (b)(1)(A)(i) to (iii), (b)(1)(C), (b)(1)(D), (b)(2), (b)(3)(B)
2. Federal Food, Drug, and Cosmetic Act, section 503B 21 U.S.C. 353b(a) opening, (a)(2)(A) to (D), (a)(5), (a)(8), (a)(9), (a)(10)(A), (b)(1)(A), (b)(1)(B)(ii), (b)(4), (b)(5), (d)(4)(A) to (C)
3. FDA guidance for industry, Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act Center for Drug Evaluation and Research, December 2016, sections III.B, III.C and III.D
4. FDA regulation, bulk drug substances that can be used to compound under section 503A 21 CFR 216.23
5. FDA regulation, products removed from the market for reasons of safety or effectiveness 21 CFR 216.24
6. Drug Supply Chain Security Act definitions 21 U.S.C. 360eee(13), including the exclusions in subparagraph (B)
7. Federal Food, Drug, and Cosmetic Act, wholesale distribution licensing 21 U.S.C. 353(e)(1)(A), (e)(4) and (e)(4)(G)
8. FDA regulation, guidelines for state licensing of wholesale prescription drug distributors 21 CFR 205.3(e), 205.3(f)(6) 205.3(f)(10) and 205.4
9. FDA, Exemptions under the Drug Supply Chain Security Act FDA web page, content current as of August 26, 2026, carrying the exemption announced August 6 2026
10. FDA, Annual Licensure Reporting by Wholesale Drug Distributors and Third-Party Logistics Providers FDA web page and the annual reporting database
11. FDA, Registered Outsourcing Facilities Facilities registered under section 503B, table updated weekly
12. FDA, Drug Establishments Current Registration Site Searchable register of establishments registered under section 510
13. FDA, Compounding Information for States FDA web page, content current as of August 28 2026
14. FDA, Drug Supply Chain Security Act Law and Policies Agency policy index, entry dated February 4 2022